Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, Komaba, Meguro-ku, Tokyo, Japan.
Jpn J Clin Oncol. 2012 Mar;42(3):226-36. doi: 10.1093/jjco/hyr194. Epub 2012 Jan 4.
This report summarizes the presentations and discussions that took place at the Fifth Joint Meeting of J-CaP and CaPSURE held in Tokyo, Japan, in July 2011. The J-CaP and CaPSURE Joint Initiative was established in 2007 with the objective of analyzing, reviewing, comparing and contrasting data on prostate cancer patients from Japan and the USA within the two important large-scale, longitudinal, observational databases-J-CaP and CaPSURE. Since its inception, the initiative has reviewed a wide range of topics and generated valuable data on the patterns of prostate cancer treatment and patient outcomes in the two geographical regions. The objectives of this 5th Joint Meeting were to provide an update on the current status of the J-CaP and CaPSURE databases, and also to discuss perspectives from a range of other Asian countries-Japan, China, Indonesia and Korea-on the use of androgen deprivation therapy for prostate cancer. The collaborators recognize that large databases, such as J-CaP and CaPSURE, provide valuable 'real-world' information, to complement data from clinical trials, which can help to advance the clinical management of prostate cancer patients worldwide. It is anticipated that in the near future, the Joint Initiative will expand globally to include patient registries from other countries so that best practice can be shared and regional differences in patients, treatments and outcomes can be explored.
本报告总结了 2011 年 7 月在日本东京举行的 J-CaP 和 CaPSURE 第五次联合会议上的演讲和讨论。J-CaP 和 CaPSURE 联合倡议于 2007 年成立,目的是分析、审查、比较和对比来自日本和美国的前列腺癌患者数据,这两个数据库分别是 J-CaP 和 CaPSURE,这两个数据库是两个重要的大型、纵向、观察性数据库。自成立以来,该倡议已经审查了广泛的主题,并生成了关于这两个地理区域前列腺癌治疗模式和患者结果的有价值的数据。第五次联合会议的目的是提供 J-CaP 和 CaPSURE 数据库的最新情况,并从日本、中国、印度尼西亚和韩国等其他亚洲国家的角度讨论使用雄激素剥夺疗法治疗前列腺癌的情况。合作者认识到,像 J-CaP 和 CaPSURE 这样的大型数据库提供了有价值的“真实世界”信息,以补充临床试验数据,这有助于推进全球前列腺癌患者的临床管理。预计在不久的将来,联合倡议将在全球范围内扩大,纳入来自其他国家的患者登记处,以便分享最佳实践,并探讨患者、治疗和结果方面的地区差异。